FeedbackLSE:FDBK -2.74% EBITDA Margin % is -389.10% as of Nov. 2025. The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Feedback ranks worse than 95.81% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Feedback's EBITDA for the
six
months ended in Nov. 2025 was £-1.61 Mil. Feedback's Revenue for the
six
months ended in Nov. 2025 was £0.41 Mil. Therefore, Feedback's EBITDA margin for the quarter that ended in Nov. 2025 was -389.10%.
Feedback (LSE:FDBK) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Feedback EBITDA Margin % Related Terms
Feedback EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Feedback's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FDBK vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Feedback's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feedback EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Feedback's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Feedback's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Feedback (LSE:FDBK) has a EBITDA Margin % of -389.10% as of Nov. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Feedback and its competitors. According to the industry distribution chart, Feedback ranks #640 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 95.8%.
Is Feedback's EBITDA Margin % too high?
Feedback's current EBITDA Margin % is -389.10%. Based on the distribution chart, Feedback ranks #640 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Feedback's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Feedback ranks #640 out of 668 companies for EBITDA Margin %. This places Feedback in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Feedback and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Feedback's current EBITDA Margin % is -389.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feedback stock overvalued right now?
Based on GuruFocus' analysis, Feedback (LSE:FDBK) is currently considered Possible Value Trap. The stock's GF Value™ is £0.14, compared to a current price of £0.07 — trading 49.3% below its estimated fair value. The current EBITDA Margin % is -389.10%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Feedback (LSE:FDBK), the current EBITDA Margin % is -389.10% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making, and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. Its operating segments include Medical Imaging and Feedback Medical Imaging India. Its products include Bleepa, a regulated communication platform for sharing clinical results and supporting multidisciplinary teamwork, and CareLocker, a patient-facing platform that provides access and control over diagnostic and clinical data.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FDBK has been successfully added to your 